Boehringer Ingelheim ubhengeze namhlanje ukuba i-US Food and Drug Administration (FDA) inike iBreakthrough Therapy Designation kunyango lwayo lophando lwenoveli, i-BI 1015550, yonyango lwe-idiopathic pulmonary fibrosis (IPF). I-BI 1015550 yi-inhibitor yomlomo, i-phosphodiesterase 4B (PDE4B) ekwaziyo ukujongana ne-pulmonary fibrosis - i-scarring engenakuguqulwa yezicubu zemiphunga ezichaphazela kakubi ukusebenza kwemiphunga - kunye nokuvutha okuhambelana nezifo eziqhubekayo ze-fibrosing interstitial lung (ILDs).
"Uphuhliso olukhawulezileyo lwe-BI 1015550 luyinxalenye ye-Boehringer Ingelheim elandelayo yonyango olunokubakho lwezifo zemiphunga ye-interstitial ezijolise ekulondolozeni ukusebenza kwemiphunga kunye nokuphucula ubomi bezigulana," utshilo uThomas Seck, MD, usekela-mongameli omkhulu, iMicimbi yezonyango kunye noLawulo, I-Boehringer Ingelheim Pharmaceuticals, Inc. “i-BI 1015550 imele i-molecule yokuqala kudidi lwe-PDE4B inhibitors efundelwa i-IPF kunye nezinye ii-ILDs eziqhubela phambili ze-fibrosing. Sakhe kwilifa lethu kwi-pulmonary fibrosis kwaye sisebenza kwinkqubela phambili yokuchongwa kunye nedatha yeklinikhi ngenjongo yokuba eli yeza inoveli linokuthi lifikelele kwizigulana ngokukhawuleza. "
INTO ONOKUYITHATHA KWELI NQAKU:
- I-BI 1015550 yi-inhibitor yomlomo, i-phosphodiesterase 4B (PDE4B) ekwaziyo ukujongana ne-pulmonary fibrosis - i-scarring engenakuguqulwa yezicubu zemiphunga ezichaphazela kakubi ukusebenza kwemiphunga - kunye nokudumba okuhambelana nezifo eziqhubekayo ze-fibrosing interstitial lung (ILDs).
- Sakhe kwilifa lethu kwi-pulmonary fibrosis kwaye sisebenza kwinkqubela phambili yokuchongwa kunye nedatha yeklinikhi ngenjongo yokuba eli yeza linoveli linokuthi lifikelele kwizigulana ngokukhawuleza.
- “Uphuhliso olukhawulezileyo lwe-BI 1015550 yinxalenye yezaliso ezilandelayo ze-Boehringer Ingelheim zonyango olunokubakho lwezifo zemiphunga ezingaphakathi ezijolise ekugcineni ukusebenza kwemiphunga kunye nokuphucula ubomi bezigulana,”.
